PATENT CLAIM ANALYSIS

Application Number: 16404059
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["424", "489000"]

Abstract:
The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Claim (Index 65):
The composition of  claim 58 , wherein the protein kinase inhibitor is dasatinib solvate.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 100.0
- Lexical Diversity: 1.48718
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16404004', '16403969', '16404027', '15248107', '15791093']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.9085872389766606
- 35 USC 102 Novelty (BERT): 0.687921648771524
- Combined Prediction Score: 0.8865206799561469
- Mean Citation Score: 853.8148140000003
- Max Citation Score: 856.69073
- Similarity Product: 684.9398540314257

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test